检索结果 - Tavi Nathanson
- Showing 1 - 3 results of 3
-
1
-
2
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis 由 Alexandra Snyder, Tavi Nathanson, Samuel A. Funt, Arun Ahuja, Jacqueline L. Buros, Matthew D. Hellmann, Eliza Chang, Bülent Arman Aksoy, Hikmat Al‐Ahmadie, Erik Yusko, Marissa Vignali, Sharon Benzeno, Mariel Elena Boyd, Meredith Moran, Gopa Iyer, Harlan Robins, Elaine R. Mardis, Taha Merghoub, Jeff Hammerbacher, Jonathan E. Rosenberg, Dean F. Bajorin
出版 2017Artigo -
3
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 由 Matthew D. Hellmann, Tavi Nathanson, Hira Rizvi, Ben Creelan, Francisco Sánchez-Vega, Arun Ahuja, Ai Ni, Jacki B. Novik, Levi Mangarin, Mohsen Abu-Akeel, Cailian Liu, Jennifer L. Sauter, Natasha Rekhtman, Eliza Chang, Margaret K. Callahan, Jamie E. Chaft, Martin H. Voss, Megan Tenet, Xuemei Li, Kelly L. Covello, Andrea Renninger, Patrik Vitazka, William J. Geese, Hossein Borghaei, Charles M. Rudin, Scott Antonia, Charles Swanton, Jeff Hammerbacher, Taha Merghoub, Nicholas McGranahan, Alexandra Snyder, Jedd D. Wolchok
出版 2018Artigo
相关主题
Biology
Cancer research
Immune system
Immunology
Immunotherapy
Medicine
T cell
Blockade
CTLA-4
Cancer
Gene
Genetics
Immune checkpoint
Internal medicine
Mutation
Oncology
Receptor
Atezolizumab
Bladder cancer
Combination therapy
Context (archaeology)
Exome sequencing
Germline mutation
Lung cancer
PD-L1
Paleontology
Pembrolizumab
Somatic cell
T-cell receptor
Targeted therapy